DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Acute Effects of Progesterone on LH Pulses During the Follicular Phase (CRM006)

Information source: University of Virginia
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Female Reproductive Physiology

Intervention: oral micronized progesterone suspension (Drug); Placebo (Drug)

Phase: N/A

Status: Active, not recruiting

Sponsored by: University of Virginia

Official(s) and/or principal investigator(s):
Christopher R. McCartney, MD, Principal Investigator, Affiliation: University of Virginia

Summary

The rapidity with which progesterone slows LH (and by inference GnRH) pulse frequency in women is unclear. The investigators hypothesize that progesterone slows LH pulse frequency within 10 hours. The investigators propose to assess this further with a randomized, cross-over, placebo-controlled study. Regularly cycling women without hyperandrogenism will be admitted to the Clinical Research Unit on cycle day 5-9 (mid-follicular phase) for a 10 hour frequent sampling study to observe LH, FSH, estradiol, progesterone, and testosterone. Either oral micronized progesterone suspension or placebo will be administered at 0900 h. During a subsequent menstrual cycle, subjects will undergo another study identical to the first except that oral progesterone will be exchanged for placebo or vice versa in accordance with a crossover design.

Clinical Details

Official title: Acute Effects of Progesterone on LH Pulses During the Follicular Phase

Study design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science

Primary outcome: Change in number of LH pulses

Secondary outcome:

Change in mean LH

Change in mean LH amplitude

Detailed description: The rapidity with which progesterone slows LH (and by inference GnRH) pulse frequency in women is unclear. The investigators hypothesize that progesterone slows LH pulse frequency within 10 hours. The investigators propose to assess this further with a randomized, cross-over, placebo-controlled study. Regularly cycling women without hyperandrogenism will be admitted to the Clinical Research Unit on cycle day 5-9 (mid-follicular phase) for a frequent sampling study. Beginning at 0900 h, blood for LH, FSH, estradiol, progesterone, and testosterone will be obtained over a 10-hour period. Either oral micronized progesterone (100 mg p. o.) suspension or placebo will be administered at 0900 h. During a subsequent menstrual cycle, subjects will undergo another study identical to the first except that oral progesterone will be exchanged for placebo or vice versa in accordance with a crossover design. The primary endpoint of interest is LH pulse frequency; the investigators will compare LH pulse frequency after progesterone administration to LH pulse frequency after placebo administration.

Eligibility

Minimum age: 18 Years. Maximum age: 30 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Subjects will be healthy women with regular menstrual cycles and no evidence of

hyperandrogenism.

- Subjects will be 18-30 years old; the investigators use a cutoff age of 30 years

because age-related alterations in the hypothalamic-pituitary-ovarian axis is uncommon before age 30 years.

- Subjects will be willing to strictly avoid pregnancy (using non-hormonal methods)

during the time of study and must be willing and able to provide informed consent. Exclusion Criteria:

- Pregnancy

- Lactation

- History of allergy to progesterone

- BMI < 18 kg/m2 or > 30 kg/m2 (underweight and obesity can affect

hypothalamic-pituitary-ovarian function)

- Excessive exercise, defined as routine and current engagement in either (a) moderate

exercise (e. g., brisk walking) exceeding 14 hours per week or (a) vigorous exercise exceeding 7 hours a week.

- Clinical hyperandrogenism (primarily hirsutism)

- Abnormally elevated free testosterone or DHEAS concentration

- A previous diagnosis of diabetes, a fasting glucose ≥ 126 mg/dl

- Abnormal TSH (subjects with adequately treated hypothyroidism, reflected by normal

TSH values, will not be excluded; or, for a new diagnosis of hypothyroidism, further study will at the least be delayed pending appropriate treatment) (confirmed on repeat)

- Abnormal prolactin (confirmed on repeat)

- Evidence of Cushing's syndrome by history or physical exam

- History of venous thromboembolism, breast/ovarian/endometrial cancer

- The investigators will exclude women with any other cancer diagnosis and/or treatment

(with the exception of basal cell or squamous skin carcinoma) unless they have remained clinically disease free (based on appropriate surveillance) for five years.

- Women with anemia (hematocrit < 36% and hemoglobin level < 12 g/dl) will be treated

with iron for a maximum of 2 sequential months before the 1st admission and/or before the 2nd admission. If they remain anemic after 2 sequential months of ferrous gluconate (325 mg bid), they will then be excluded from further participation in the study.

- Women with a significant history of cardiac or pulmonary dysfunction (e. g., known or

suspected congestive heart failure; known or suspected coronary atherosclerosis; asthma requiring systemic intermittent corticosteroids; etc.) will be excluded.

- Women with liver enzymes, alkaline phosphatase, or bilirubin > 1. 5 times upper limit

of normal (confirmed on repeat) will be excluded, with the exception that mild bilirubin elevations will be accepted in the setting of known Gilbert's syndrome.

- Abnormal sodium or potassium concentrations (confirmed on repeat); bicarbonate

concentrations <20 or >30 (confirmed on repeat)

- Women with abnormal renal function (i. e., serum creatinine > 1. 4) will be excluded

(confirmed on repeat)

- Due to the amount of blood being drawn in the study, subjects with body weight < 110

pounds will be excluded from the study

- Being a study of the acute effects of progesterone on the hypothalamic-pituitary

unit, subjects must not take hormonal medications (e. g., oral contraceptives) or other medications known to affect the reproductive axis for 60 days prior to the study and during the study.

Locations and Contacts

Center for Research in Reproduction, Charlottesville, Virginia 22908, United States
Additional Information

Starting date: May 2012
Last updated: June 22, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017